Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

PANAX PLANT EXTRACT AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Publication Date:
    June 17, 2021
  • Additional Information
    • Document Number:
      20210177923
    • Appl. No:
      16/479221
    • Application Filed:
      December 04, 2017
    • Abstract:
      A Panax plant extract and a pharmaceutical composition and the use thereof. The mass ratio of Rk1 and Rg5 in the Panax plant extract is 1:1.0-1.5, and the content of Rg3, Rg5 and Rk1 in the extract is relatively high. The extract can be used to prepare a drug for treating chronic heart failure, coronary stable angina, arrhythmia, diabetes and complications thereof, Meniere's disease, hyperlipemia, fatty liver, Alzheimer's disease, dymenorrhea, metabolic syndrome, gout, tumours or vascular leak syndrome.
    • Assignees:
      SHANGHAI HONGYITANG BIOPHARMACEUTICAL CO., LTD (Shanghai, CN)
    • Claim:
      1. A Panax plant extract, comprising GinsenosideRg3, GinsenosideRk1 and GinsenosideRg5, and wherein, a mass ratio of the GinsenosideRk1 and to the GinsenosideRg5 is 1:(1.0-1.5).
    • Claim:
      2. The Panax plant extract of claim 1, wherein, 0.5≤(Rg5+Rk1)/Rg3≤1.5, wherein Rg5 is a mass percentage of the GinsenosideRg5, Rk1 is a mass percentage of the GinsenosideRk1 and Rg3 is a mass percentage of the GinsenosideRg3.
    • Claim:
      3. The Panax plant extract of claim 1, wherein, the GinsenosideRg3 comprises 20(R)-GinsenosideRg3 and 20(S)-GinsenosideRg3 with a mass ratio of 1:1.5.
    • Claim:
      4. The Panax plant extract of claim 1, further comprising GinsenosideRg2, GinsenosideRh1 and GinsenosideRh2, wherein, 60%≤(Rg5+Rk1+Rg3)/(Rg5+Rk1+Rg3+Rg2+Rh1+Rh2)≤100% Rg3 is a mass percentage of the GinsenosideRg3, Rg5 is a mass of percentage of the GinsenosideRg5, Rk1 is a mass percentage of the GinsenosideRk1, Rg2 is a mass percentage of the GinsenosideRg2, Rh1 is a mass percentage of the GinsenosideRh1 and Rh2 is a mass percentage of the GinsenosideRh2.
    • Claim:
      5. The Panax plant extract of claim 4, wherein, the GinsenosideRg2 comprises 20(R)-GinsenosideRg2 and 20(S)-GinsenosideRg2 with a mass ratio of 1.5:2.5.
    • Claim:
      6. The Panax plant extract of claim 1, wherein, the Panax plant extract comes from a Panax plant, and the Panax plant is at least one selected from the group consisting of ginseng, red ginseng, Korean ginseng, pseudo-ginseng, Panax japonicus and American ginseng.
    • Claim:
      7. A pharmaceutical composition, comprising the Panax plant extract of claim 1 and vectors acceptable to drug.
    • Claim:
      8. The pharmaceutical composition of claim 7, wherein, a dosage form of the pharmaceutical composition is one selected from the group consisting of tablet, capsule, oral liquid, mouth agentia, granules, electuary, pill, pulvis, mastic, sublimed preparation, suspensoid, powder, solution, injection, suppository, spray, drops, and patch, and the tablet is an orally disintegrating tablet.
    • Claim:
      9. A method of using the Panax plant extract of claim 1 in preparing a drug for treating chronic heart failure, coronary stable angina, arrhythmia, diabetes and complications thereof, Meniere's disease, hyperlipemia, fatty liver, Alzheimer's disease, dymenorrhea, metabolic syndrome, gout, tumours or vascular leak syndrome, comprising the following step: using the Panax plant extract in preparing the drug.
    • Claim:
      10. The Panax plant extract of claim 2, further comprising GinsenosideRg2, GinsenosideRh1 and GinsenosideRh2, wherein, 60%≤(Rg5+Rk1+Rg3)/(Rg5+Rk1+Rg3+Rg2+Rh1+Rh2)≤100%, Rg2 is a mass percentage of the GinsenosideRg2, Rh1 is a mass percentage of the GinsenosideRh1 and Rh2 is a mass percentage of the GinsenosideRh2.
    • Claim:
      11. The Panax plant extract of claim 3, further comprising GinsenosideRg2, GinsenosideRh1 and GinsenosideRh2, wherein, 60%≤(Rg5+Rk1+Rg3)/(Rg5+Rk1+Rg3+Rg2+Rh1+Rh2)≤100%, Rg3 is a mass percentage of the GinsenosideRg3, Rg5 is a mass of percentage of the GinsenosideRg5, Rk1 is a mass percentage of the GinsenosideRk1, Rg2 is a mass percentage of the GinsenosideRg2, Rh1 is a mass percentage of the GinsenosideRh1 and Rh2 is a mass percentage of the GinsenosideRh2.
    • Claim:
      12. The pharmaceutical composition of claim 7, wherein, 0.5≤(Rg5+Rk1)/Rg3≤1.5; wherein Rg5 is a mass percentage of the GinsenosideRg5, Rk1 is a mass percentage of the GinsenosideRk1 and Rg3 is a mass percentage of the-GinsenosideRg3.
    • Claim:
      13. The pharmaceutical composition of claim 7, wherein, the GinsenosideRg3 comprises 20(R)-GinsenosideRg3 and 20(S)-GinsenosideRg3 with a mass ratio of 1:1.5.
    • Claim:
      14. The pharmaceutical composition of claim 7, wherein, the Panax plant extract further comprises GinsenosideRg2, GinsenosideRh1 and GinsenosideRh2, wherein 60%≤(Rg5+Rk1+Rg3)/(Rg5+Rk1+Rg3+Rg2+Rh1+Rh2)≤100%, Rg3 is a mass percentage of the GinsenosideRg3, Rg5 is a mass of percentage of the GinsenosideRg5, Rk1 is a mass percentage of the GinsenosideRk1, Rg2 is a mass percentage of the GinsenosideRg2, Rh1 is a mass percentage of the GinsenosideRk1 and Rh2 is a mass percentage of the GinsenosideRh2.
    • Claim:
      15. The pharmaceutical composition of claim 14, wherein, the GinsenosideRg2 comprises 20(R)-GinsenosideRg2 and 20(S)-GinsenosideRg2 with a mass ratio of 1.5:2.5.
    • Claim:
      16. The pharmaceutical composition of claim 7, wherein, the Panax plant extract comes from a Panax plant, and the Panax plant is at least one selected from the group consisting of ginseng, red ginseng, Korean ginseng, pseudo-ginseng, Panax japonicus and American ginseng.
    • Claim:
      17. The method of claim 9, wherein, 0.5≤(Rg5+Rk1)/Rg3≤1.5; wherein Rg5 is a mass percentage of the GinsenosideRg5, Rk1 is a mass percentage of the GinsenosideRk1 and Rg3 is a mass percentage of the-GinsenosideRg3.
    • Claim:
      18. The method of claim 9, wherein, the GinsenosideRg3 comprises 20(R)-GinsenosideRg3 and 20(S)-GinsenosideRg3 with a mass ratio of 1:1.5.
    • Claim:
      19. The method of claim 9, wherein, the Panax plant extract further comprises GinsenosideRg2, GinsenosideRk1 and GinsenosideRh2, wherein 60%≤(Rg5+Rk1+Rg3)/(Rg5+Rk1+Rg3+Rg2+Rh1+Rh2)≤100%, Rg3 is a mass percentage of the GinsenosideRg3, Rg5 is a mass of percentage of the GinsenosideRg5, Rk1 is a mass percentage of the GinsenosideRk1, Rg2 is a mass percentage of the GinsenosideRg2, Rh1 is a mass percentage of the GinsenosideRk1 and Rh2 is a mass percentage of the GinsenosideRh2.
    • Claim:
      20. The method of claim 19, wherein, the GinsenosideRg2 comprises 20(R)-GinsenosideRg2 and 20(S)-GinsenosideRg2 with a mass ratio of 1.5:2.5.
    • Current International Class:
      61; 61; 61; 61; 61; 61; 61; 61
    • Accession Number:
      edspap.20210177923